Centene (CNC) Stock Still Looks Cheap After A 122% Run

Centene stock has surged over the past year, yet the latest valuation checks still lean on the cheap side for this managed care company. For investors, the question is whether that mix of strong recent returns and an undervalued label can coexist for long.

• Centene has delivered a 121.6% gain over the past year, which puts extra focus on whether the recent share price already reflects the main improvements in the business.
• Analysts pointing to margin recovery and steadier earnings quality may support higher valuations, while ongoing policy risk around Medicaid exposure can limit how much investors are willing to pay for the stock.
• With a high value score that indicates the broader checks lean cheap, Centene screens as undervalued on most of the usual valuation measures.

The issue now is whether Centene’s current share price still offers enough valuation appeal after such a strong 1 year run.

Spot opportunities similar to Centene's recent rerating by scanning a curated set of 45 high quality undervalued stocks that combine strong fundamentals with pricing that still screens as cheap.

Is Centene a Bargain on Sales?

P/S is a useful cross-check for a company like Centene, where revenue scale and contract coverage are key parts of the story.

Centene trades on a P/S of about 0.2x, which is well below the Healthcare industry average of around 1.4x, and also below a peer group average of roughly 1.7x. The fair ratio framework, which considers Centene’s mix of growth prospects, profitability profile, size, and risk factors, indicates a P/S of about 0.9x as a more typical level. That is materially higher than where the stock is now.

Recent analyst support around potential margin recovery and cleaner execution has not pushed the P/S anywhere near those benchmark levels. As a result, the stock still appears to trade at a sizeable discount to both industry levels and the modelled fair value.

On the P/S multiple, Centene stock currently appears undervalued relative to both sector norms and its own fair ratio benchmark.

See what the numbers say about this price — find out in our valuation breakdown.

The Centene Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Centene help you connect the current valuation puzzle with the specific assumptions that would need to hold on growth, margins and earnings for the stock to be worth materially more or less than today’s price, and they sit on the company’s Community page. Rather than focusing on a single multiple or model, each Narrative lays out the key inputs behind its fair value view so you can track them against actual results over time.

Community views on Centene sit far apart, with one side leaning into margin recovery potential and the other focused on Medicaid and regulatory risk.

Bull case: 10% undervalued

"Centene's Medicaid business is expected to see margin recovery as rate adjustments align better with member acuity, which could improve Medicaid-related revenue and net margins..."

Read the full Bull Case to see why Centene could be undervalued

Bear case: 14% overvalued

"Rising government scrutiny over managed care costs and ongoing legislative focus on pricing transparency are set to intensify regulatory pressure on Centene, increasing the risk of lower reimbursement rates and margin compression across Medicaid and Marketplace lines..."

Read the full Bear Case to see why Centene could be overvalued

Do you think there's more to the story for Centene? Head over to our Community to see what others are saying!

The Bottom Line

Centene still appears undervalued on the main market multiples, even after a strong 1-year share price move. That suggests the current discount is less about backward-looking results and more about how investors weigh future Medicaid and regulatory risk against the potential for steadier margins.

The key question from here is whether Centene can deliver cleaner execution and margin stability that convinces the market to close that gap, or whether the current valuation reflects a permanent risk premium that remains in place.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com